Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

Belite Bio, Inc

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

COMPANY INVITES INDIVIDUAL AND INSTITUTIONAL INVESTORS, AS WELL AS ADVISORS AND ANALYSTS, TO ATTEND ONLINE AT VIRTUALINVESTORCONFERENCES.COM COMPANY INVITES INDIVIDUAL AND INSTITUTIONAL INVESTORS, AS WELL AS ADVISORS AND ANALYSTS, TO ATTEND ONLINE AT VIRTUALINVESTORCONFERENCES.COM

BELITE BIO TO PRESENT AT THE DBVIC - DEUTSCHE BANK ADR VIRTUAL INVESTOR CONFERENCE NOVEMBER 4TH

SAN DIEGO, OCT. 29, 2025 (GLOBE NEWSWIRE) -- BELITE BIO INC(NASDAQ: BLTE) (BELITE OR THE COMPANY), A CLINICAL-STAGE DRUG DEVELOPMENT COMPANY FOCUSED ON ADVANCING NOVEL THERAPEUTICS TARGETING DEGENERATIVE RETINAL DISEASES THAT HAVE SIGNIFICANT UNMET MEDICAL NEEDS, TODAYANNOUNCED THAT THE EXECUTIVE MANAGEMENT TEAM WILL PRESENT AT THE DEUTSCHE BANK AMERICAN DEPOSITARY RECEIPT (ADR) VIRTUAL INVESTOR CONFERENCE HOSTED BY VIRTUALINVESTORCONFERENCES.COM, ON NOVEMBER 4, 2025. DETAILS OF THE PRESENTATION ARE AS FOLLOWS:

BELITE BIO TO PARTICIPATE IN THE DEUTSCHE BANK ADR VIRTUAL INVESTOR CONFERENCE

SAN DIEGO, OCT. 15, 2025 (GLOBE NEWSWIRE) -- BELITE BIO, INC. (NASDAQ: BLTE), A CLINICAL-STAGE DRUG DEVELOPMENT COMPANY FOCUSED ON ADVANCING NOVEL THERAPEUTICS TARGETING DEGENERATIVE RETINAL DISEASES THAT HAVE SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED THAT THE CENTER FOR DRUG EVALUATION OF CHINA'S NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) HAS AGREED TO ACCEPT THE NEW DRUG APPLICATION (NDA) WITH PRIORITY REVIEW FOR TINLAREBANT FOR THE TREATMENT OF STARGARDT DISEASE BASED ON THE INTERIM ANALYSIS RESULTS FROM THE PHASE 3 DRAGON TRIAL.

BELITE BIO ANNOUNCES CHINA NMPA AGREES TO NEW DRUG APPLICATION WITH PRIORITY REVIEW BASED ON INTERIM ANALYSIS RESULTS FOR THE TREATMENT OF STARGARDT DISEASE WITH TINLAREBANT

SAN DIEGO, SEPT. 08, 2025 (GLOBE NEWSWIRE) -- BELITE BIO, INC ("BELITE BIO" OR THE "COMPANY") (NASDAQ: BLTE), A CLINICAL-STAGE DRUG DEVELOPMENT COMPANY FOCUSED ON ADVANCING NOVEL THERAPEUTICS TARGETING DEGENERATIVE RETINAL DISEASES THAT HAVE SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED THAT IT HAS ENTERED INTO SECURITIES PURCHASE AGREEMENTS WITH LEADING HEALTHCARE INVESTORS FOR A PRIVATE PLACEMENT IN PUBLIC EQUITY FINANCING (THE PIPE) THAT IS EXPECTED TO RESULT IN GROSS PROCEEDS OF APPROXIMATELY $125 MILLION, BEFORE DEDUCTING PLACEMENT AGENT FEES AND ESTIMATED OFFERING EXPENSES, AND UP TO AN ADDITIONAL APPROXIMATELY $150 MILLION IN GROSS PROCEEDS IF THE ACCOMPANYING WARRANTS ARE FULLY EXERCISED FOR CASH.

BELITE BIO ANNOUNCES UP TO $275 MILLION UPSIZED PRIVATE PLACEMENT FINANCING BY LEADING HEALTHCARE INVESTORS

SAN DIEGO, AUG. 11, 2025 (GLOBE NEWSWIRE) -- BELITE BIO,INC(NASDAQ: BLTE), A CLINICAL-STAGE DRUG DEVELOPMENT COMPANY FOCUSED ON ADVANCING NOVEL THERAPEUTICS TARGETING DEGENERATIVE RETINAL DISEASES THAT HAVE SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE30, 2025, AND PROVIDED A GENERAL BUSINESS UPDATE.

BELITE BIO REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

SAN DIEGO, AUG. 07, 2025 (GLOBE NEWSWIRE) -- BELITE BIO, INC ("BLTE" OR THE "COMPANY") (NASDAQ: BLTE), A CLINICAL-STAGE DRUG DEVELOPMENT COMPANY FOCUSED ON ADVANCING NOVEL THERAPEUTICS TARGETING DEGENERATIVE RETINAL DISEASES THAT HAVE SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A SECURITIES PURCHASE AGREEMENT FOR THE PURCHASE AND SALE OF 230,770 AMERICAN DEPOSITARY SHARES (ADSS) AND WARRANTS TO PURCHASE 230,770 ADSS, AT A PURCHASE PRICE OF $65 PER ADS AND ACCOMPANYING WARRANT, PURSUANT TO A REGISTERED DIRECT OFFERING. THE OFFERING IS EXPECTED TO RESULT IN GROSS PROCEEDS OF APPROXIMATELY $15 MILLION, BEFORE DEDUCTING OFFERING EXPENSES, AS WELL AS THE POTENTIAL FOR ADDITIONAL PROCEEDS OF APPROXIMATELY $15 MILLION FROM THE EXERCISE OF FIVE-YEAR WARRANTS ISSUED IN THE OFFERING. THE CLOSING OF THE OFFERING IS EXPECTED TO OCCUR ON OR ABOUT AUGUST 8, 2025, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

BELITE BIO ANNOUNCES REGISTERED DIRECT OFFERING OF $15 MILLION

- 500 SUBJECTS ENROLLED ACROSS THE UNITED STATES, THE UNITED KINGDOM, FRANCE, CZECH REPUBLIC, SWITZERLAND, CHINA, TAIWAN, AND AUSTRALIA

BELITE BIO ANNOUNCES COMPLETION OF ENROLLMENT IN THE PIVOTAL GLOBAL PHASE 3 PHOENIX TRIAL EVALUATING ORAL TINLAREBANT IN GEOGRAPHIC ATROPHY

SAN DIEGO, MAY 21, 2025 (GLOBE NEWSWIRE) -- BELITE BIO, INC. (NASDAQ: BLTE), A CLINICAL-STAGE BIOPHARMACEUTICAL DRUG DEVELOPMENT COMPANY FOCUSED ON ADVANCING NOVEL THERAPEUTICS TARGETING DEGENERATIVE RETINAL DISEASES THAT HAVE SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED BREAKTHROUGH THERAPY DESIGNATION FOR TINLAREBANT FOR THE TREATMENT OF STARGARDT DISEASE (STGD1) BASED ON THE PREVIOUSLY REPORTED INTERIM DATA FROM THE ONGOING PHASE 3 DRAGON TRIAL.THERE ARE CURRENTLY NO APPROVED TREATMENTS FOR STGD1.

BELITE BIO ANNOUNCES FDA GRANTING OF BREAKTHROUGH THERAPY DESIGNATION FOR TINLAREBANT FOR THE TREATMENT OF STARGARDT DISEASE

SAN DIEGO, MAY 13, 2025 (GLOBE NEWSWIRE) -- BELITE BIO, INC (NASDAQ: BLTE), A CLINICAL-STAGE BIOPHARMACEUTICAL DRUG DEVELOPMENT COMPANY FOCUSED ON ADVANCING NOVEL THERAPEUTICS TARGETING DEGENERATIVE RETINAL DISEASES THAT HAVE SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025, AND PROVIDED A BUSINESS UPDATE.

BELITE BIO REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BELITE BIO, INC TO PRESENT AT THE DBVIC - DEUTSCHE BANK ADRVIRTUAL INVESTOR CONFERENCE MAY 15TH

SAN DIEGO, MAY 12, 2025 (GLOBE NEWSWIRE) -- BELITE BIO, INC (NASDAQ: BLTE), A CLINICAL-STAGE BIOPHARMACEUTICAL DRUG DEVELOPMENT COMPANY FOCUSED ON ADVANCING NOVEL THERAPEUTICS TARGETING DEGENERATIVE RETINAL DISEASES THAT HAVE SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED THAT THE EXECUTIVE MANAGEMENT TEAM WILL PARTICIPATE IN FOUR UPCOMING INVESTOR CONFERENCES. DETAILS OF THE PRESENTATIONS ARE AS FOLLOWS:

Belite Bio, Inc

BLTE

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Belite Bio, Inc

BLTE.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

BLTE